abs435.txt	introduction	the	rising	cost	of	cancer	drugs	may	make	treatment	unaffordable	forsome	patients		patients	often	rely	on	drug	manufacturer-administeredpharmaceutical	assistance	programs	(paps)	to	obtain	drugs	and	reduced	or	no	cost	the	overall	usage	of	paps	within	cancer	care	delivery	is	unknown		methods	weincluded	all	cancer	patients	across	an	academically	affiliated		integrated	healthsystem	in	north	carolina	during	2014	(	n	=	8591)		we	identified	the	subset	ofpatients	receiving	pap	assistance	to	afford	one	or	more	cancer	drugs		in	order	tocalculate	the	proportion	of	patients	receiving	pap	assistance		and	the	retailvalue	of	the	assistance		results	among	8591	cancer	patients		215	unique	patientssubmitted	a	total	of	478	successful	pap	requests	for	cancer	drugs		40%	ofpap-utilizing	patients	were	uninsured		23%	had	medicaid	coverage		20%	hadmedicare	coverage		2%	were	dual	medicare/medicaid	eligible		and	14%	werecommercially	insured		among	all	cancer	patients	who	received	medical	treatment	6	0%	required	pap	assistance		whereas	10	6%	receiving	an	oral	agent	required	papassistance		the	proportion	receiving	pap	assistance	varied	substantially	by	drug	ranging	from	<1%	of	patients	(e	g		carboplatin		methotrexate)	to	50%	of	patients(e	g		ponatinib		temsirolimus)		the	majority	of	the	retail	value	obtained	was	fororal	agents		including	$1	556	575	of	imatinib	and	$1	449	633	of	dasatinib		whichwere	the	two	drugs	with	the	highest	aggregate	retail	value		conclusions	asubstantial	proportion	of	cancer	patients	receive	private	charitable	assistanceto	obtain	standard-of-care	treatments		this	includes	patients	with	federal	andprivate	insurance		suggesting	an	inability	of	patients	to	meet	cost-sharingrequirements	
